Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
AbbVie
(NY:
ABBV
)
193.90
+0.50 (+0.26%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about AbbVie
< Previous
1
2
...
7
8
9
10
11
12
13
14
15
...
65
66
Next >
Pinterest To Rally Over 20%? Here Are 10 Top Analyst Forecasts For Monday
February 05, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
3 Fabulous Dividend Stocks to Buy in February
February 04, 2024
These stocks offer great dividends and more.
Via
The Motley Fool
7 Dividend Stocks That Pay Me More Than $500 Per Month
February 03, 2024
These stocks pay safe, reliable, and growing dividends.
Via
The Motley Fool
AbbVie (ABBV) Q4 2023 Earnings Call Transcript
February 02, 2024
ABBV earnings call for the period ending December 31, 2023.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Biden Administration To Send Pharma Companies Opening Offers For Medicare Program's First Ever Drug Price Negotiations
February 02, 2024
The Inflation Reduction Act's impact on drug prices. Medicare challenges pharmaceutical costs, offering relief to seniors and addressing the soaring prices in the U.S. healthcare system.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
AbbVie Earnings Preview
February 01, 2024
Via
Benzinga
This Is What Whales Are Betting On AbbVie
January 31, 2024
Via
Benzinga
Stock Market Handles Huge Earnings Week, Fed's Powell, Jobs Report: Weekly Review
February 02, 2024
The Dow led the major indexes higher. Big techs diverged on results.
Via
Investor's Business Daily
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
AbbVie Lifts Long-Term Outlook For New Immunology Drugs, Even As Q4 Revenue and Profit Fall
February 02, 2024
AbbVie reports Q4 earnings with adjusted EPS at $2.79, beating consensus. Sees FY 2024 EPS of $11.05-$11.25. Raises 2027 outlook for key products.
Via
Benzinga
AbbVie turns a corner; patent cliff fears were overblown
February 02, 2024
AbbVie's patent cliff is already a thing of the past with Skyrizi and Rinvoq outperforming and other assets also strong. Dividends are safe, growth is back.
Via
MarketBeat
Topics
Intellectual Property
Exposures
Intellectual Property
AbbVie's Options Frenzy: What You Need to Know
January 24, 2024
Via
Benzinga
AbbVie Expects Two Of Its Biggest Drugs To Bring In $27 Billion In 2027. And Neither One Is Humira.
February 02, 2024
The company raised its long-term guidance for four products on Friday. Two will top $27 billion in 2027 sales, the company says.
Via
Investor's Business Daily
AbbVie Posts Less-Than-Healthy Financial Results For 2023
February 02, 2024
Pharmaceuticals company AbbVie reported its Q4 and full year financial results for 2023.
Via
Talk Markets
Nasdaq Futures Climb As Meta, Amazon Gains Offset Apple Slide: Analyst Points to 2 Factors Reinforcing Bullish Outlook This Year
February 02, 2024
Stock futures are pointing upwards on Friday as traders assess earnings reports from Meta Platforms, Inc.
Via
Benzinga
Earnings Scheduled For February 2, 2024
February 02, 2024
Companies Reporting Before The Bell • W.W. Grainger (NYSE:GWW) is likely to report quarterly earnings at $8.05 per share on revenue of $4.04 billion.
Via
Benzinga
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for January 2024
January 31, 2024
Biotech stocks are warming up in January and look to continue upward in 2024 as the economy improves. Here are three to check out.
Via
InvestorPlace
Topics
Economy
Exposures
Economy
Best Income Stocks 2024
January 31, 2024
The pros and cons of 7 companies in 4 different sectors.
Via
Talk Markets
Goldman Sachs, AbbVie And A Major Chipmaker: CNBC's 'Final Trades'
January 30, 2024
On CNBC’s "Halftime Report Final Trades," Steve Weiss of Short Hills Capital Partners said Taiwan Semiconductor Manufacturing Company Limited (NYSE: TSM)
Via
Benzinga
3 Stocks Enjoying Favorable Analyst Coverage
January 29, 2024
We see daily analyst upgrades and downgrades, coming with price targets. They can be helpful tools for investors, providing a more structured plan and helping to inject positivity surrounding future...
Via
Talk Markets
Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate
January 29, 2024
Via
Get News
Exposures
Product Safety
AbbVie's Transformational 2023, Analyst Anticipates Growth in 2024 Amid Competitive Pressures
January 29, 2024
AbbVie's growth outlook in 2024 as William Blair upgrades, highlighting strong performance in Humira erosion management, strategic acquisitions, and a 3.8% dividend yield.
Via
Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: McGrath RentCorp (Nasdaq – MGRC), Science 37 Holdings, Inc. (Nasdaq – SNCE), Eagle Bulk Shipping Inc. (NYSE - EGLE), Cerevel Therapeutics Holdings, Inc. (Nasdaq –
January 29, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate
January 29, 2024
--News Direct--
Via
News Direct
Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate
January 29, 2024
New York, Jan. 29, 2024 - (Plato Data) -- Corbus Pharmaceuticals (NASDAQ:CRBP) jumped on Friday after announcing positive data from a small group of cancer patients who received its antibody-drug...
Via
TheNewswire.com
Exposures
Product Safety
Tech Titans Microsoft, Apple Lead 'Magnificent Seven' Earnings Wave This Week: Can Mega-Caps Ignite Market Optimism?
January 29, 2024
An analyst sees the Satya Nadella-led company's earnings to be the key barometer for AI spending.
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
2 High-Yield Healthcare Stocks to Buy With Both Hands and 1 to Avoid for Now
January 28, 2024
All three of these stocks offer attractive dividend yields, but one looks risky.
Via
The Motley Fool
ABBV: This Top Biotech Just Went On A Buying Spree
January 25, 2024
AbbVie stock is a buy following its recent merger & acquisition activity (Immunogen and Cerevel).
Via
Talk Markets
2 No-Brainer Dividend Stocks to Buy for the New Year
January 25, 2024
These companies have fantastic track records of maintaining and raising their payouts.
Via
The Motley Fool
3 Dividend Stars Every Investor Should Own to Survive a Market Crash
January 24, 2024
Prepare for the worst but hope for the best by buying dividend stocks for a market crash that can provide both growth and income.
Via
InvestorPlace
AbbVie Stock Moves With Rising Relative Strength, Still Room To Grow
January 24, 2024
AbbVie shows improving price performance, earning an upgrade to its IBD Relative Strength Rating
Via
Investor's Business Daily
< Previous
1
2
...
7
8
9
10
11
12
13
14
15
...
65
66
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.